Skip to main content

Table 1 Base-case probabilities and cost estimates in the decision tree analysis

From: Cost-effectiveness analysis of neoadjuvant versus adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer patients during initial treatment phase

Event

Probability

Source

NAC

AC

Receiving surgery

1

1

Brandt et al. [10]

Receiving chemotherapy

1

1

Postoperative complication

 No ≥ 3 grade complication

0.82

0.91

 ≥ 3 grade complication

0.14

0.07

 Death

0.04

0.02

Adverse event of chemotherapy (> 3 grade)

0.15

0.38

OS

9.1 years

9.1 years